Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials

摘要: Angiogenesis is an integral process in carcinogenesis, and molecular inhibitors of angiogenic factors are currently being tested as treatments for cancer. Sunitinib oral multitargeted tyrosine-kinase inhibitor that blocks activation through the stem cell-factor receptor (Kit) platelet-derived growth-factor receptor. has shown potent antitumor activity against several solid tumors, including renal cell carcinoma, gastrointestinal stromal neuroendocrine tumors Phase II/III trials. Recently, sunitinib been used to treat other cancers, such lung cancer, pancreatic chondrosarcoma, esophageal bladder glioma, aggressive fibromatosis, also showed potential efficacy progression-free survival overall survival. In this review, we examine a molecular-targeted therapy patients with different types cancers.